Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris' Board of Directors (the "Committee") granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the "2024 Inducement Plan"). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris' new President and Chief Operating Officer, nonstatutory stock options to purchase 375,000 shares of its common stock and 107,000 restricted stock units under the 2024 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
賓夕法尼亞州韋恩，2024年12月3日（環球新聞通訊）—— aclaris therapeutics公司（納斯達克：ACRS）（"公司"或"aclaris"），是一家專注於開發新型藥物候選者以治療免疫炎症疾病的臨床階段生物製藥公司，今天宣佈，2024年12月2日起，aclaris董事會的薪酬委員會（"委員會"）授予4名新員工非法定股票期權，總計購買其普通股251,000股和73,000個限制性股票單位，依據aclaris therapeutics, inc. 2024激勵計劃（"2024激勵計劃"）。此外，自2024年12月2日起，委員會還授予aclaris的新總裁兼首席運營官Hugh Davis博士非法定股票期權，允許其購買375,000股普通股和107,000個限制性股票單位，依據2024激勵計劃。這些股票期權和限制性股票單位的授予旨在作爲新員工與aclaris成爲員工的誘因，符合納斯達克上市規則5635(c)(4)。
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individuals' entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
2024激勵計劃僅用於向曾不是aclaris員工或非員工董事（或者在經過真實的非就業期後）個人授予股權獎，以作爲對這些個人進入aclaris工作的重要誘因，依據納斯達克上市規則5635(c)(4)的規定。
The options have an exercise price of $3.96 per share, which is equal to the closing price of Aclaris' common stock on December 2, 2024. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third, and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2024 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit award agreement, as applicable, covering the grant.
這些期權的行使價格爲每股3.96美元，與2024年12月2日aclaris普通股的收盤價相等。每個期權和限制性股票單位獎勵將在接收者的開始控件日期後的第一個、第二個、第三個和第四個週年日各解鎖25％的股份，並可按適用情況行使，前提是每位員工在這些解鎖日期仍繼續與aclaris保持僱傭關係。這些期權和限制性股票單位獎勵受制於aclaris 2024激勵計劃的條款和條件，以及適用的股票期權協議或限制性股票單位獎勵協議的條款和條件。
Aclaris Therapeutics Contact:
Aclaris Therapeutics 聯繫方式：
investors@aclaristx.com
investors@aclaristx.com
譯文內容由第三人軟體翻譯。
